Advanced Therapeutics in Rheumatoid Arthritis (RA)
Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis
Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid
Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical
trial in a clinical situation using an electronic medical record (EMR).
Phase:
Phase 4
Details
Lead Sponsor:
Lawson Health Research Institute
Collaborator:
Academic Medical Organization of Southwestern Ontario